Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 28;11:2408. doi: 10.1038/s41598-021-82128-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Triptonide inhibits TNBC cell growth in vitro and in vivo. (a) Chemical structures of triptonide and triptolide. (b) Left, representative images showing the effects of 0.2 µM triptonide treatment for 24-h in HCC1806, BT549, and MDA-MB-231 cells. Magnification, × 200. Right, quantified effects of 0.2 µM triptonide on cell growth measured by CellTiter-Glo assays. HCC1806, BT549, and MDA-MB-231 cells were treated for 24 h (D1), 48 h (D2) and 72 h (D3). Each bar is presented as mean ± SD (n = 3). (c) Left, immunoblotting of p-JNK, total (t)-JNK, cleaved PARP in HCC1806 cells treated with 0.2 µM triptonide. Right, apoptosis analysis of HCC1806 cells treated with 0.2 µM triptonide for 20 h by the FITC Annexin V/PI apoptosis assay. (d) Comparisons of MDA-MB-231 xenograft mammary tumors in mice treated with vehicle or triptonide. Graphs show tumor volume changes with time and tumor weight at harvest. Each bar is presented as mean ± SD (n = 4). **, p < 0.01. (e) Expression of Ki67 and cleaved PARP in MDA-MB-231 xenograft tumor tissues examined by immunohistochemistry assays. Magnification, × 400.